Skip to main content

Table 1 Summary of eleven first-in-human drugs presented at this year's ASCO meeting.

From: First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

Drug name

Target

Route

Tumor sites enrolled

Common low-grade adverse effects

Dose-limiting toxicities

RPTD

Clinical efficacy

Phase II studies planned/o pen

BMS-663513

CD-137 agonist

i.v.

Melanoma Renal cell Ovarian

Fatigue

Rash/pruritis

Diarrhea

Fever

Neutropenia

Transaminitis

TBD (range from 0.1–5 mg/kg every 3 weeks)

6% PR 15% SD†

Melanoma

CT-322

VEGFR-2

i.v.

Misc. solid tumors and NHL

Proteinuria

Hypertension

Proteinuria

RPLS

Retinal vascular occlusion

MTD of 2 mg/kg/week, RPTD not specified

49% SD†

GBM

CVX-045

Thrombospondin

i.v.

Misc. solid tumors

Fatigue

GI

Dyspnea

Headache

Dizziness

None

1 radiation pneumonitis

1 death (bowel obstruction)

12 mg/kg/week

5% PR 33% SD

TBD

GDC-0449

Smoothened

oral

Misc. solid tumors

Dysguesia

Hyponatremia

Fatigue

None

150 mg daily

11% PR

11% SD

Colorectal

Ovarian

BCC

GRN163L

Telomerase

i.v.

Misc. solid tumors

Prolonged PTT

GI

Fatigue

Thrombocytopenia

One death (unknown cause)

TBD

TBD

TBD

LY2181308

Survivin

i.v.

Misc. solid tumors

Fever

Fatigue

Prolonged PTT

Nausea

Headache

750 mg daily for 3 days, then weekly

10% SD

Prostate

PF-00562271

FAK

oral

Misc. solid tumors

GI

Headache

Fatigue

Dizziness

Headache

Nausea

125 mg twice daily

17% SD

TBD

RAV12

RAAG12

i.v.

GI cancers

Diarrhea

Abdominal discomfort

Transaminitis

Diarrhea

Abdominal discomfort

Transaminitis

0.75 mg/kg twice weekly

2% PR 20% SD†

Pancreas

Colorectal

RTA 402

NF-κB and STAT3

oral

Misc. solid tumors and NHL

GI

Fatigue

Anorexia

Dysguesia

ALT elevation

900 mg/day

7% CR + PR

40% SD†

Pancreas

Melanoma

XL765

PI3K and mTOR

oral

Misc. solid tumors

Transaminitis

Diarrhea

Anorexia

Fatigue

Transaminitis

Diarrhea

Possibly 60 mg twice daily

26% SD

TBD

Survivin vaccine

Survivin

s.c.

Melanoma

Injection site reactions

Fever

Lymph node swelling

None

TBD

8% CR+PR

TBD

  1. †Clinical efficacy was not available at time of presentation for all patients enrolled in these studies, therefore these response rates do not represent the whole study cohort and may change in the future
  2. Abbreviations: TBD – to be determined; MTD – maximum tolerated dose; RPTD – recommended phase II dose; CR – complete response; PR – partial response; SD – stable disease; i.v. – intravenous; Misc – miscellaneous; NHL – non-Hodgkin's lymphoma; GBM – gliobastome multiforme; PTT – partial thromboplastin time; s.c. – deep subcutaneous; GI – gastrointestinal (including all 3 of nausea/vomiting/diarrhea); BCC – basal cell carcinoma; RPLS – Reversible posterior leucoencephalopathy syndrome